LYNPARZA may help treat your unique type of breast cancer
Breast cancer is a disease that occurs in different cells in the breast. It is said to have metastasized when it has spread through blood vessels and lymph vessels to other parts of the body.
LYNPARZA is an active treatment that gives certain patients the option of treating their specific kind of metastatic breast cancer. LYNPARZA is taken by mouth, so there's no need to go to an infusion center.

BRCA mutations and LYNPARZA
Your BRCA status plays an important role in your treatment with LYNPARZA. If you have an inherited BRCA mutation, LYNPARZA may be right for you. Talk to your doctor about getting a genetic test to see if you have an inherited BRCA mutation. The sooner you do this after diagnosis, the better informed you and your doctor will be to help determine your treatment plan.
LEARN ABOUT GENETIC TESTINGLYNPARZA is prescribed for two groups of people with
HER2*-negative metastatic breast cancer and an inherited BRCA mutation.
HR†-positive metastatic breast cancer after chemotherapy and hormonal therapy
Triple-negative metastatic breast cancer after chemotherapy
LYNPARZA was tested against chemotherapy in a metastatic breast cancer clinical study, which included these 2 groups of patients. Results from this clinical study are shown below.
*HER2: human epidermal growth factor receptor 2; †HR: hormone receptor.
LYNPARZA could give you MORE TIME progression free

Talk to your doctor early about LYNPARZA for this type of metastatic breast cancer.
CLINICAL STUDY RESULTS
Metastatic breast cancer
The OlympiAD study tested 302 people with an inherited BRCA mutation and HER2-negative metastatic breast cancer that was previously treated with chemotherapy, and if HR-positive, treated with hormonal therapy (205 people took LYNPARZA and 97 took chemotherapy).
LYNPARZA delayed disease progression by 7 months LYNPARZA was shown to delay disease progression by a median of 7 months compared with 4.2 months for patients who were given certain chemotherapies.
LYNPARZA lowered the risk of disease progression or death by 42%
People treated with LYNPARZA were 42% less likely to have their cancer grow or spread than those on chemotherapy.
2x the percentage of people saw their tumors shrink than those taking certain chemotherapies
LYNPARZA

87 out of 167 people
CERTAIN CHEMOTHERAPIES

15 out of 66 people
52% of people taking LYNPARZA saw their tumors shrink compared to 23% of those taking certain chemotherapies.
These data are based on patients with tumors that responded to LYNPARZA (167 patients) or chemotherapy (66 patients).

LYNPARZA patient information
The Breast Cancer Patient Brochure gives you more information on starting and continuing treatment with LYNPARZA.
DOWNLOAD BROCHURE
Downloadable resources
LYNPARZA patient information
Get more information on starting and continuing treatment with LYNPARZA.
Tips for managing your treatment
Learn more about the potential side effects of LYNPARZA and how you should work with your doctor to manage them.
LYNPARZA caregivers
Our Caregiver Brochure provides useful tips and information. Learn more about the importance of looking after yourself as a caregiver.